title: Clinical, Morphologic, and Pathologic Features Associated With Increased FDG Uptake in Schwannoma.
abstract: OBJECTIVE
  The objective of this study was to investigate the clinical, morphologic, and pathologic features associated with increased18F-FDG uptake in benign schwannomas.
  
  
  METHODS
  Twenty-two schwannomas in 22 patients (age range, 25-81 years) who had FDG PET or PET/CT scans and subsequently underwent surgical re-section were retrospectively analyzed. The maximum standardized uptake value (SUVmax) was compared with patient age, sex, tumor location (gastrointestinal vs nongastrointestinal origin), tumor size, gross appearance, intratumoral cellularity, intratumoral infiltration of inflammatory cells, presence of peritumoral lymphoid cuffs, and expression status of glucose transporters 1 and 3 on tumor cells.
  
  
  RESULTS
  The SUVmaxof schwannomas ranged from 1.5 to 17.3 (median, 3.7). Significantly higher SUVmaxwas observed in gastrointestinal schwannomas (n = 4) compared with nongastrointestinal schwannomas (n = 18, p = 0.007) and in schwannomas with peritumoral lymphoid cuffs (n = 5) compared with those without peritumoral lymphoid cuffs (n = 17, p = 0.001). A significant correlation was seen between tumor location and the presence of peritumoral lymphoid cuffs (p < 0.001). Age, sex, tumor size, gross appearance, intratumoral cellularity, intratumoral inflammatory cell infiltration, and expression status of glucose transporters 1 and 3 on tumor cells had no significant correlation with SUVmax.
  
  
  CONCLUSIONS
  Gastrointestinal schwannomas and schwannomas with peritumoral lymphoid cuffs may be associated with elevated FDG uptake. Knowledge of the features of schwannomas associated with increased uptake may be helpful to avoid misinterpretation of benign schwannomas as malignancy.
authors.affiliation: 1 Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Hospital, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.|2 Department of Radiology, Rakuwakai Otowa Hospital, Kyoto, Japan.
authors.forename: Kanae K
authors.initials: KK
authors.lastname: Miyake
authors.affiliation: 1 Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Hospital, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.
authors.forename: Yuji
authors.initials: Y
authors.lastname: Nakamoto
authors.affiliation: 3 Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
authors.forename: Tatsuki R
authors.initials: TR
authors.lastname: Kataoka
authors.affiliation: 3 Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
authors.forename: Chiyuki
authors.initials: C
authors.lastname: Ueshima
authors.affiliation: 4 Shiga Medical Center Research Institute, Shiga, Japan.
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Higashi
authors.affiliation: 5 Department of Diagnostic Pathology, Shiga Medical Center for Adults, Shiga, Japan.
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Terashima
authors.affiliation: 6 Department of Diagnostic Radiology, Kurashiki Central Hospital, Okayama, Japan.
authors.forename: Koya
authors.initials: K
authors.lastname: Nakatani
authors.affiliation: 1 Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Hospital, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.|7 Diagnostic Imaging Group, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan.
authors.forename: Tsuneo
authors.initials: T
authors.lastname: Saga
authors.affiliation: 8 Department of Radiology, Shiga Medical Center for Adults, Shiga, Japan.
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Minami
authors.affiliation: 1 Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Hospital, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.
authors.forename: Kaori
authors.initials: K
authors.lastname: Togashi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D051274:Glucose Transporter Type 3 / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009442:Neurilemmoma / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology*; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014018:Tissue Distribution
chemical_list: D014408:Biomarkers, Tumor; D051274:Glucose Transporter Type 3; D019275:Radiopharmaceuticals; C495687:SLC2A3 protein, human; D019788:Fluorodeoxyglucose F18
keywords: 18F-FDG; PET; gastrointestinal schwannoma; peritumoral lymphoid cuff; schwannoma